Overview

A Study of GMA301 in Subjects With Pulmonary Arterial Hypertension

Status:
Recruiting
Trial end date:
2022-06-10
Target enrollment:
Participant gender:
Summary
A Randomized, Placebo-Controlled, Double-blind, Dose Escalation Study to Assess Safety, Efficacy and Pharmacokinetics of GMA301 Injection in Subjects with Pulmonary Arterial Hypertension
Phase:
Phase 1
Details
Lead Sponsor:
Gmax Biopharm LLC.